A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Next-Generation Cancer Immunotherapies, features profiles of Borean Pharma, OncoMed Pharmaceuticals, ProNAi Therapeutics and Receptor Logic. Plus these Start-Ups across Health Care: CeraPedics, DiObex and Endothelix.

Receptor Logic has a means of making antibodies that mimic the scouting and identifying functions of T-cells by binding to peptides that appear on the surface of cells, within the frame of the major histocompatability complex. The start-up thinks its antibodies will accelerate research on T-cell-stimulating vaccines (versus prophylactic ones) and will ultimately serve as therapeutics in their own right.

New approaches to cancer immunotherapy promise to change the face of cancer care in a way that will reverberate through the field for years to come. In this issue, we profile Borean Pharma, OncoMed Pharmaceuticals and Receptor Logic.

In Vivo briefly summarizes the technologies of these recently founded companies: AGI Therapeutics Ltd., Angiosyn Inc., etexx Biopharmaceuticals Inc., Nuvios Inc., Orthonics Inc. and Receptor Logic Ltd.